Form 8-K Filing: Zivo Bioscience, Inc. - Officer Changes

Zivo Bioscience, Inc. reported a change in its Chief Financial Officer position on December 19, 2025. Keith R. Marchiando resigned as CFO, with his resignation effective immediately and employment ending on December 31, 2025. He will receive his current salary until December 31, 2026, and retains an option to acquire 150,000 shares of common stock at an exercise price of $7.96 per share, exercisable until June 30, 2027. William A. Sullivan has been appointed as the Interim Chief Financial Officer, effective December 19, 2026. Mr. Sullivan, with over 25 years of financial experience, particularly in the life sciences and biotechnology sectors, will serve as an independent contractor at a rate of $285.00 per hour for an initial period of 60 days, with automatic successive one-month renewals. The agreement includes confidentiality obligations and restrictions on soliciting employees or diverting business.